

# Clinical trials of sitagliptin 50mg bid monotherapy

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>sitagliptin 50mg bid monotherapy vs placebo</b>			
Scott* (sit vs pbo) , 2007 n=NA follow-up:	sitagliptin 50 mg b.i.d versus placebo	-	
<b>sitagliptin 50mg bid monotherapy vs glipizide</b>			
Scott* (sit vs glipi) , 2007 n=NA follow-up: 12 weeks	sitagliptin 50mg bid versus glipizide 5mg to 20 mg dailyitm	patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise	double-blind

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

## References

### Scott\* (sit vs pbo), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80 [[17156104](#)] [10.1111/j.1742-1241.2006.01246.x](https://doi.org/10.1111/j.1742-1241.2006.01246.x)

### Scott\* (sit vs glipi), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80 [[17156104](#)] [10.1111/j.1742-1241.2006.01246.x](https://doi.org/10.1111/j.1742-1241.2006.01246.x)

Entry terms: sitagliptin, sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431,